NVSNovartis PharmaceuticalsSigning up patients
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Extensive-stage Small Cell Lung Cancer (ES-SCLC)
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 80 (planned)
- Started
- Jun 16, 2026
- Main results expected
- Mar 3, 2031
- Fully finished
- Mar 3, 2031
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
All study parts: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)
Measured over: Up to approximately 2 years
All study parts: Incidence and severity of dose-limiting toxicities (DLTs)
Measured over: 28 days
Phase II Group A: Overall response rate (ORR) as per RECIST v1.1
Measured over: Up to approximately 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT07564401 · record last updated 2026-10-19 · checked 2026-11-09 15:47 UTC